ACTU at a glance
ACTUATE THERAPEUTICS, INC. (ACTU, SEC CIK 1652935) filed its latest 10-K annual report on March 26, 2026, a 10-Q quarterly report on August 14, 2026, an 8-K current report on July 17, 2026 and Form 4 insider filings as recently as August 14, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of June 30, 2026, 13 institutional investment managers tracked by SignalX reported holding ACTUATE THERAPEUTICS, INC. (ACTU) shares worth $1.2 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 13 funds
- $1.2M · −2 vs prior quarter
- Latest 8-K
- Jul 17, 2026
- Item 3.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- No material risk-factor details provided beyond general investment-risk warning
AI summary of the ACTU 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule
- Nasdaq MVLS deficiency after market value remained below $50 million from June 1–July 14, 2026
- Common stock remains listed and trading on Nasdaq Global Market under ACTU
Item 5.07: Submission of Matters to a Vote of Security Holders
- Stockholders re-elected Aaron G.L. Fletcher and Jason Keyes to three-year Class II director terms ending at the 2029 annual meeting
- Jason Keyes received 16,727,875 votes for and 32,397 withheld, indicating strong shareholder support
Item 7.01: Regulation FD Disclosure
- Exhibit deemed furnished, not “filed,” under Exchange Act Section 18
- Disclosure generally excluded from incorporation by reference into future Securities Act or Exchange Act filings
AI summaries of ACTU 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ACTU
Don't miss the next ACTU filing
- Alerts as it files. A push when ACTU files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ACTU, by share count.
- Ask anything. An AI agent that reads every ACTU filing and answers with sources.
ACTU alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| SCHMITT DANIEL M | F | Aug 14, 2026 | 120,521 | $1.01 |
| SCHMITT DANIEL M | M | Aug 14, 2026 | 272,056 | - |
| SCHMITT DANIEL M | M | Aug 14, 2026 | 272,056 | - |
| Fletcher Aaron G.L. | A | May 21, 2026 | 15,000 | - |
| Zabrowski Dan | A | May 21, 2026 | 15,000 | - |
| RONNEBERG AMY L | A | May 21, 2026 | 15,000 | - |
| THOMSON TODD S | A | May 21, 2026 | 15,000 | - |
| Keyes Jason A | A | May 21, 2026 | 15,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Operating Income | -$25.0M | -$25.2M | -$22.5M | |
| Net Income | -$24.7M | -$27.3M | -$22.2M | |
| Balance Sheet | ||||
| Total Assets | $3.0M | $9.3M | $14.0M | |
| Equity | -$99.6M | $104K | $7.9M | |
| ROE | 24.8% | -26189.1% | -280.5% | |
| Per Share | ||||
| EPS | $-17.24 | $-3.26 | $-1.06 | |
| Cash Flow | ||||
| Operating CF | -$21.6M | -$21.8M | -$19.2M | |
Source: XBRL data in ACTUATE THERAPEUTICS, INC. (ACTU)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate ACTU share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 13 | $1.2M |
| Q1 2026 | 15 | $3.1M |
| Q4 2025 | 11 | $7.2M |
| Q3 2025 | 11 | $5.1M |
| Q2 2025 | 10 | $3.8M |
| Q1 2025 | 7 | $831,000 |
| Q4 2024 | 1 | $114,000 |
| Q3 2024 | 1 | $25,000 |
- AQR Capital Management+100.4K (+370%)
- Goldman Sachs Group+23.1K (+186%)
- JPMorgan Chase & Co+3.8K (+97%)
- PNC Financial Services+2.5K (+14682%)
- BlackRock−337.1K (-79%)
- Northern Trust−76.6K (-78%)
- State Street Corp−44.2K (-67%)
- Vanguard Capital Management LLC−7.1K (-2%)
- FMR LLC (Fidelity)−5.7K (-63%)
- Millennium Management+96.7K
- Vanguard Portfolio Management LLC−55.5K
- BNY Mellon−15.4K
- Bank of America Corp−11.0K
Source: 13F-HR filings on SEC EDGAR (aggregated from 69 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ACTU filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Aug 14, 2026 | - | - | - |
| 10-Q | Aug 14, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Jul 17, 2026 | - | Analysis | - |
| 4 | May 22, 2026 | - | - | |
| 8-K | May 22, 2026 | - | Analysis | |
| 4 | May 22, 2026 | - | - | |
| 4 | May 22, 2026 | - | - | |
| 4 | May 22, 2026 | - | - | |
| 4 | May 22, 2026 | - | - | |
| 4 | May 22, 2026 | - | - | |
| 4 | May 22, 2026 | - | - | |
| 10-Q | May 14, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 11, 2026 | - | Analysis | |
| 8-K | May 6, 2026 | - | Analysis | |
| 4 | Apr 1, 2026 | - | - | - |
| 4 | Apr 1, 2026 | - | - | - |
| 4 | Apr 1, 2026 | - | - | - |
| 10-K | Mar 26, 2026 | Dec 31, 2025 | - | |
| 4 | Feb 13, 2026 | - | - | |
| 8-K | Jan 12, 2026 | - | - | |
| 4 | Jan 7, 2026 | - | - | |
| SC 13G | Dec 17, 2025 | - | - | |
| 8-K | Nov 28, 2025 | - | - | |
| 10-Q | Nov 13, 2025 | Sep 30, 2025 | Analysis | |
| 10-Q | Aug 14, 2025 | Jun 30, 2025 | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
- ACET · Adicet Bio IncPharmaceutical Preparations
ACTU SEC filings: frequently asked questions
Which institutions hold ACTU stock?
As of June 30, 2026, the largest ACTUATE THERAPEUTICS, INC. (ACTU) holders among the 13F filers tracked by SignalX were Vanguard Capital Management LLC ($602,000), AQR Capital Management ($195,000), Millennium Management ($148,000), BlackRock ($138,000), Goldman Sachs Group ($54,000). 13F-HR reports are filed up to 45 days after each quarter ends.
What did ACTU report in its latest 8-K?
ACTUATE THERAPEUTICS, INC. (ACTU) filed an 8-K on July 17, 2026 reporting Item 3.01 (Notice of Delisting or Failure to Satisfy a Continued Listing Rule). Nasdaq MVLS deficiency after market value remained below $50 million from June 1–July 14, 2026.
What are the latest ACTU SEC filings?
ACTUATE THERAPEUTICS, INC. (ACTU) filed its latest 10-K annual report on March 26, 2026, a 10-Q quarterly report on August 14, 2026, an 8-K current report on July 17, 2026 and a Form 4 insider filing on August 14, 2026.
What is ACTU's SEC CIK number?
ACTUATE THERAPEUTICS, INC. (ACTU)'s SEC Central Index Key (CIK) is 1652935. EDGAR lists every ACTU filing under that number.
Ask anything about ACTU
The research agent reads ACTU's filings, financials, insider trades and 13F holders, then answers with sources.